| Code | CSB-RA004959MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Galiximab, targeting CD80 (B7-1), a critical costimulatory molecule expressed primarily on antigen-presenting cells including B lymphocytes, activated T cells, and dendritic cells. CD80 plays a pivotal role in T cell activation by binding to CD28 and CTLA-4 receptors, thereby regulating immune responses and maintaining peripheral tolerance. Dysregulated CD80 expression is implicated in various pathological conditions, including B cell malignancies such as non-Hodgkin lymphoma, autoimmune disorders, and transplant rejection, making it an important target for immunological research.
Galiximab, the reference antibody, is a primatized IgG1 monoclonal antibody that was investigated in clinical trials for the treatment of relapsed or refractory follicular lymphoma and other B cell non-Hodgkin lymphomas. This biosimilar provides researchers with a valuable tool for investigating CD80-mediated immune regulation, studying B cell biology, exploring costimulatory pathway modulation, and developing novel therapeutic strategies for hematological malignancies and immune-mediated diseases. The antibody facilitates in vitro and in vivo studies examining immune checkpoint mechanisms and antibody-dependent cellular cytotoxicity.
There are currently no reviews for this product.